Futura Medical (FUM)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 19.7 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | -5.1% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Futura Medical plc. revenues decreased 53% to L75K. Net loss increased 20% to L2.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Administrative Expenses increase of 41% to L1.1M (expense), Interest Income decrease of 24% to L18K (income). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 0 |
Futura Medical plc (Futura) develops products for the consumer healthcare market. The Company’s principal activity includes research and development of medical devices and pharmaceutical drugs and their commercial exploitation with the focus being on transdermal products for sexual healthcare and pain relief management. Futura’s sexual healthcare products included CSD500, PET500 and MED2002. Its pain relief management included TPR100 and TPR100-Rx. Futura has developed a transdermal delivery technology, DermaSys, for the absorption of active molecules through the skin. CSD500 is aimed at helping men maintain a firmer erection during intercourse whilst wearing a condom. MED2002 is a topical gel for the treatment of male erectile dysfunction. TPR100 is a product for the provision of topical pain relief. TPR100-Rx is a topical product available on prescription for the treatment of more profound indications, such as osteoarthritis and rheumatic pain.
Directors: James Barder (CEO) 50, Derek Martin (Fin. Dir.) , David Davies (Exec. Dir.) ,
No. of Employees: 3 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 77,492,946 |
| Free Float | 55.0m (71.0%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | , GUILDFORD, GU2 7YG, United Kingdom |
| Web | http://www.futuramedical.com/ |
| Phone | +44 1483 685670 |
| Contact | Anthony Clayden (Fin. Dir.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | BDO LLP |
| 6th Jun | Notification of Major Interest in Shares |
| 31st May | Total Voting Rights |
| 22nd May | Block Listing Update |
| 21st May | Notification of Interim Results |
| 9th May | Director Share Dealings |
| 7th May | Result of AGM |
Recent ↓
